Friday, May 15: Enhertu’s Early Breast Cancer Expansion, Tecentriq’s MRD Approval, and Aardvark’s Clinical Hold
BioBrief’s Friday episode covers a regulatory-heavy day in biopharma, with two meaningful FDA oncology decisions landing against a weak biotech tape.
In today’s BioBrief:
Enhertu — The FDA approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate in two early-stage HER2-positive breast cancer settings, including adjuvant use after residual invasive disease.
Tecentriq and Signatera — Roche’s Tecentriq was approved for ctDNA-positive muscle-invasive bladder cancer after cystectomy, alongside Natera’s Signatera CDx companion diagnostic.
Aardvark Therapeutics — The FDA placed ARD-101 under a full clinical hold after cardiac safety concerns, resetting the outlook for the company’s Prader-Willi syndrome program.
Market pulse — Biotech underperformed the broader market, with XBI down 3.08 percent and IBB down 2.63 percent versus a 1.2 percent decline in the S&P 500.
Catalyst watch — Next steps include Enhertu adoption in earlier breast cancer, real-world uptake of MRD-guided bladder cancer treatment, and Aardvark’s planned unblinding of available Phase 3 data.
Today’s theme: strong FDA oncology decisions, weak biotech risk appetite, and a reminder that safety can quickly reshape a small-cap development story.
20 May 2026
Week Ahead by BioBrief, Sunday, May 17: Ralinepag’s PAH Data, ASCO Abstracts, and Enhertu’s FDA Approvals
BioBrief’s special week-ahead edition previews the key biotech and biopharma events to watch for the week of May 18, with pulmonary data, oncology positioning, and FDA regulatory updates in focus.
In today’s BioBrief:
United Therapeutics / ralinepag — Phase 3 ADVANCE OUTCOMES data in pulmonary arterial hypertension showed a 55 percent reduction in clinical worsening risk, setting up a planned NDA filing in the second half of 2026.
ASCO abstracts — Regular ASCO abstracts are scheduled for release on Thursday, May 21, creating an important oncology positioning event ahead of the full meeting.
Enhertu — Daiichi Sankyo and AstraZeneca enter the week with two new FDA approvals for Enhertu in HER2-positive early-stage breast cancer.
ATS respiratory watch — United Therapeutics’ Tyvaso data in idiopathic pulmonary fibrosis, Insmed’s ARIKAYCE data in MAC lung disease, and Savara’s molgramostim updates are also in focus.
Market pulse — Biotech enters the week under pressure, with XBI down about 3 percent last week and IBB down about 1.8 percent, while the S&P 500 was slightly positive.
Catalyst watch — The week’s core question is whether strong pulmonary data and ASCO setup can offset a risk-off small-cap biotech tape.
This episode is designed for biotech investors, operators, founders, pharma BD teams, analysts, and scientifically literate listeners tracking clinical, regulatory, and market-moving events.
15 May 2026
Thursday, May 14: Kyverna’s Autoimmune CAR-T Filing, BridgeBio’s Encaleret NDA, and Agios’ Mitapivat sNDA
BioBrief covers a selective biotech session driven by regulatory execution, rare-disease filings, and continued investor interest in differentiated clinical-stage stories.
In today’s BioBrief:
Kyverna / miv-cel — Kyverna continued to rally after initiating a rolling BLA submission for miv-cel in stiff person syndrome, a potential milestone for autoimmune CAR-T therapy beyond oncology.
BridgeBio / encaleret — BridgeBio’s encaleret NDA in autosomal dominant hypocalcemia type 1 remained in focus after Phase 3 CALIBRATE data showed strong calcium-normalization results versus standard therapy.
Agios / mitapivat — Agios advanced mitapivat through an sNDA seeking accelerated approval in sickle cell disease, with FDA alignment on the confirmatory trial design.
Bristol Myers Squibb / Hengrui Pharma — Bristol Myers’ broad Hengrui collaboration continued to shape discussion around China-originated pipeline sourcing and large-pharma business development.
Market pulse — XBI rose about 0.9 percent while IBB gained about 0.3 percent, with investors rewarding clear regulatory and clinical catalysts rather than broad speculative risk.
Catalyst watch — Watch for Kyverna’s BLA completion and filing acceptance, BridgeBio’s NDA review designation, and upcoming Agios hematology data visibility.
Today’s episode is about regulatory execution and modality validation driving biotech performance more than broad market risk appetite.
Contact BioBrief
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of BioBrief?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
